BP
NBIX icon

Ballentine Partners’s Neurocrine Biosciences NBIX Stock Holding History

Ballentine Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$565K Buy
3,354
+112
+3% +$16.6K 0.01% 528
2026
Q1 		$427K Buy
+3,242
New +$430K 0.01% 590
2025
Q1 		– Sell
-1,675
Closed -$229K – 976
2024
Q4 		$229K Buy
+1,675
New +$207K ﹤0.01% 727

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

Ballentine Partners's NBIX Position: Q2 2026 in Review

Ballentine Partners increased its Neurocrine Biosciences (NBIX) stake by 3.5% in Q2 2026, buying an estimated $16.6K and bringing the position to 3,354 shares worth $565K. The position accounts for 0.01% of the portfolio, ranked #528.

Ballentine Partners first reported a position in NBIX in Q4 2024 and has held it in 3 quarters since. 113 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Ballentine Partners held 3,354 shares of Neurocrine Biosciences worth $565K as of Q2 2026.
  • Ballentine Partners bought 112 Neurocrine Biosciences shares in Q2 2026, an estimated $16.6K.
  • Neurocrine Biosciences made up 0.01% of Ballentine Partners's portfolio in Q2 2026, its #528 holding.
  • Ballentine Partners first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 3 quarters since.
  • 113 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.